Patent · US Active

Biomarker to measure drug efficacy in enteropathic disease

US8535946B2 · kind B2 · utility

0Cited by

0References

15Claims

0Family size

Assignee

The Board of Trustees of the Leland Stanford Junior University · US

Inventors

Chaitan Khosla · Palo Alto, US
Michael Bethune · Pasadena, US

Key dates

Filing date	Aug 28, 2008
Grant date	Sep 17, 2013
Priority date	—
Expiry date	Jan 15, 2029

Classification

Technology area (CPC Y)Emerging Cross-Sectional Technologies
CPC primaryY10T436/147777
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The response of a patient with an enteropathic disease to therapy, particularly a candidate therapy in a clinical trial setting, is assessed by detecting the ability of the patient to metabolize an orally administered CYP3A substrate. The CYP3A metabolism may be monitored in a variety of ways. Conveniently, the appearance of a metabolite of the CYP3A substrate is detected in a patient sample over a period of time following oral administration, e.g. in urine, plasma, breath, saliva, etc. The CYP3A substrate is optionally labeled, e.g. with an isotopic, fluorescent, etc. label.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.